•RDBPC trial of yeast-derived selenium 200ug/day in 1312 participants
•
•Reduced rates of lung, prostate and colorectal cancers over 7.7 years
•
•Self-reported T2 diabetes HR 1.55 [95% CI:1.03,
2.23]
•
•T2D risk greater if baseline Se >121.6ng/ml. HR 2.7 [CI: 1.3, 5.61]
Equivalent to 1.5 umol/l
•
•Trial results initially lead to large Se/Vit E primary prevention trial SELECT